Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response

Rambabu, Naresh; Mathew, Mano Joseph; Kaveri, Srini V.; Bayry, Jagadeesh

doi:10.1016/j.autrev.2021.102850

Cited by 4 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies used additional indexes, including red blood cell distribution width, percentage of lymphocyte, and total bile acid [ 27 ]. Recently, some studies explored the usefulness of transcriptomics to predict response to initial immunoglobulin treatment in KD [ 28 , 29 ]. While our current work showed that differential lipid profiles could stratify IVIG sensitivity from a different perspective.…”

Section: Discussionmentioning

confidence: 99%

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment

et al. 2023

View full text Add to dashboard Cite

Kawasaki Disease (KD) is an acute inflammatory disorder associated with systemic vasculitis. Intravenous immunoglobulin (IVIG) is an effective therapy for KD, yet, about 20% of cases show IVIG resistance with persistent inflammation. The lipid profile in IVIG-resistant KD patients and the relationship between lipid characteristics and IVIG resistance remain unknown. In this study, serum samples from twenty KD patients with different IVIG responses (sensitive, intermediate, or resistant) were collected both before and after treatment, and lipidomic analysis was performed using high-performance liquid chromatography-mass spectrometry. As a result, before treatment, six lipid species were found as the most variant features, in which all the top decreased lipids in the IVIG-resistant group were lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE), suggesting the potential to be IVIG-resistant markers in pretreatment diagnosis. During treatment, lipidomic changes showed a weaker response in the IVIG-resistant group. After treatment, LPC and LPE species exhibited lower in the IVIG-resistant group and negative correlation with the inflammatory markers, indicating that the unique metabolism may occur among IVIG-responsiveness. These results might contribute to diagnosing IVIG-resistant patients more accurately for alternative therapy and to a better understanding of how lipid metabolism is associated with IVIG sensitiveness/resistance in KD.

show abstract

Section: Discussionmentioning

confidence: 99%

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment

et al. 2023

View full text Add to dashboard Cite

show abstract

Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison

et al. 2021

View full text Add to dashboard Cite

Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system

Segú-Vergés

Caño²,

Calderón–Gómez

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Intravenous immunoglobulin (IVIg) is used as treatment for several autoimmune and inflammatory conditions, but its specific mechanisms are not fully understood. Herein, we aimed to evaluate, using systems biology and artificial intelligence techniques, the differences in the pathophysiological pathways of autoimmune and inflammatory conditions that show diverse responses to IVIg treatment. We also intended to determine the targets of IVIg involved in the best treatment response of the evaluated diseases. Our selection and classification of diseases was based on a previously published systematic review, and we performed the disease characterization through manual curation of the literature. Furthermore, we undertook the mechanistic evaluation with artificial neural networks and pathway enrichment analyses. A set of 26 diseases was selected, classified, and compared. Our results indicated that diseases clearly benefiting from IVIg treatment were mainly characterized by deregulated processes in B cells and the complement system. Indeed, our results show that proteins related to B-cell and complement system pathways, which are targeted by IVIg, are involved in the clinical response. In addition, targets related to other immune processes may also play an important role in the IVIg response, supporting its wide range of actions through several mechanisms. Although B-cell responses and complement system have a key role in diseases benefiting from IVIg, protein targets involved in such processes are not necessarily the same in those diseases. Therefore, IVIg appeared to have a pleiotropic effect that may involve the collaborative participation of several proteins. This broad spectrum of targets and ‘non-specificity’ of IVIg could be key to its efficacy in very different diseases.

show abstract

Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response

Cited by 4 publications

References 51 publications

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment

Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison

Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system

Contact Info

Product

Resources

About